Ukraine boasts several advantages for sponsors considering the country as a location for clinical research. Its alignment with the EU and harmonization with ICH-GCP standards, high standards in education (in particular clinical and medical training), recent national programs aimed at developing a strong clinical research sector, and general economic initiatives aimed attracting international investment make Ukraine an attractive location for international sponsors.
Cromos Pharma began working in Ukraine in 2006 and established a representative office in Kyiv in 2008. Since then, our highly experienced team in Ukraine has consistently delivered exceptional results for international sponsors.
132 Holosiivskyi ave., 14-A office, Kyiv, O3127, Ukraine
With a population of over 330 million, a well-developed medical infrastructure, an ethnically diverse patient population, and the largest concentration of biotechnology and pharma companies, the United States remains an unequivocal leader and trendsetter in clinical research. Therefore, it is not surprising that half of the world’s clinical trials are conducted in the United States. In addition to the agile regulatory framework with fast initiation timelines, world-leading scientific minds, and high-quality clinical trial data, inclusion of US clinical sites is essential for drug registration with the FDA. Cromos Pharma has a strong track record of conducting clinical research in the US since 2018. Additionally, the company has a unique advantage of offering a balanced approach of including both US and ex-US clinical sites that helps accelerate recruitment and saves time and resources.
Bulgaria ranks top 20 in the world in clinical trials performed and offers great potential for pharmaceutical companies and contract research organizations. Bulgaria is considered one of Europe’s clinical research hubs. Around 190 new studies are started every year in the country with approximately 12,000 patients annually enrolled. Bulgarian Association of Clinical Research (BACR) is advocating for high standard in conducting clinical trials and adherence to the requirements of the international standards.
Croatia provides a natural conduit between EU and non-EU countries, providing an advantage of the Croatian language which is easily understood by the non-EU countries surrounding it. Croatia has a rich heritage in terms of science and good experience in clinical research conduct. As a result many contract research organizations chose Croatia for clinical trials conduct.
The Czech Republic is a well-established location for clinical trials conduct with a strong track record of generating high quality clinical trials data. In recent years, it has developed a reputation as an attractive location for niche clinical trials including hematologic malignancies, gene and cell therapies, and rare diseases. Cromos Pharma began its operations in the Czech Republic in 2010 and established a representative office in Prague in 2015.
The healthcare sector in Estonia is rapidly developing. The government of Estonia is constantly working to improve the clinical research environment in the country. The number of study centers has grown and the annual number of submitted clinical trial protocols have steadily increased over the last two decades. .
Georgia offers international sponsors significant benefits that include a rapid regulatory approval process, substantial naïve patient populations in a wide range of therapeutic indications, skilled medical personnel, and a conducive economic environment for doing business. Cromos Pharma began conducting clinical research in Georgia in 2013. Since then, our Tbilisi-based operation has grown exponentially, managing numerous successful regional and global studies in a broad range of therapeutic indications.
Hungary boasts several key advantages for sponsors considering this country as a destination for their clinical research. Its membership in the EU, high educational standards, recent launch of national programs aimed at developing a strong medical research sector, and general economic initiatives aimed at attracting international investment all position Hungary as an attractive location. Each year approximately 20,000 Hungarian patients participate in clinical trials. Cromos Pharma established its office in Budapest in 2016.
There are many benefits to conducting clinical research in Kazakhstan, its strategic geography being one of them. Kazakhstan is a transcontinental country located between Europe and Central Asia, and it’s health demographics draw influence from both continents. This is one reason why an increasing number of biopharmaceutical companies are considering Kazakhstan as a venue for conducting its clinical research. Cromos Pharma began operations in Kazakhstan in 2017, where it initially conducted phase 3 oncology trials, but since has broadened its scope of services. The company opened a regional office in Almaty in 2021.
There is a stable increase in clinical trials in Latvia over the last 10 years. GCP trainings are well organized by the Medicine Information Centre and most of the investigators are GCP trained. Following the European Union accession, Latvia has implemented EU directives 2001/20 and 2005/28, and incorporated GCP guidelines into the national law.
Lithuania offers companies a business model favorable to the conduct of clinical research, which is increasingly recognized by many key players in the sector. More than 90 international biotech, pharma and medical companies, including global ones, have chosen Lithuania as a location to conduct their studies.